PuSH - Publikationsserver des Helmholtz Zentrums München

Export: TXT Text RIS Endnote (RIS) BIB BibTeX
Herold, T. ; Metzeler, K.H. ; Vosberg, S. ; Hartmann, L. ; Röllig, C.* ; Stölzel, F.* ; Schneider, S.* ; Hubmann, M. ; Zellmeier, E.* ; Ksienzyk, B.* ; Jurinovic, V.* ; Pasalic, Z.* ; Kakadia, P.M.* ; Dufour, A.* ; Graf, A.* ; Krebs, S.* ; Blum, H.* ; Sauerland, M.C.* ; Büchner, T.* ; Berdel, W.E.* ; Woermann, B.J.* ; Bornhäuser, M.* ; Ehninger, G.* ; Mansmann, U.* ; Hiddemann, W. ; Bohlander, S.K.* ; Spiekermann, K. ; Greif, P.A.

Isolated trisomy 13 defines a genetically homogenous AML subgroup with high frequency of mutations in spliceosome genes and poor prognosis.

Blood 124, 1304-1311 (2014)
Verlagsversion DOI PMC
Closed
Open Access Green möglich sobald Postprint bei der ZB eingereicht worden ist.
Isolated trisomy 13 (AML+13) is a rare chromosomal abnormality in acute myeloid leukemia (AML), and its prognostic relevance is poorly characterized. We analyzed the clinical course of 34 AML+13 patients enrolled in the German AMLCG-1999 and SAL trials and studied their biological characteristics by exome sequencing, targeted sequencing of candidate genes and gene expression profiling. Relapse-free (RFS) and overall survival (OS) of AML+13 patients were inferior compared to other ELN Intermediate-II patients (n=855) (median RFS, 7.8 vs 14.1 months, p=0.006; median OS 9.3 vs. 14.8 months, p=0.004). Besides the known high frequency of RUNX1 mutations (75%), we identified mutations in spliceosome components in 88%, including SRSF2 codon 95 mutations in 81%, of AML+13 patients. Moreover, recurring mutations were detected in ASXL1 (44%) and BCOR (25%). Two patients carried mutations in CEBPZ, suggesting that CEBPZ is a novel recurrently mutated gene in AML. Gene expression analysis revealed a homogenous expression profile including upregulation of FOXO1 and FLT3 and downregulation of SPRY2. This is the most comprehensive clinical and biological characterization of AML+13 to date, and reveals a striking clustering of lesions in a few genes, defining AML+13 as a genetically homogenous leukemia subgroup with alterations in a few critical cellular pathways. These studies were registered at clinicaltrials.gov, identifiers: AMLCG-1999: NCT00266136; AML96: NCT00180115; AML2003: NCT00180102; and AML60+: NCT00893373.
Impact Factor
Scopus SNIP
Web of Science
Times Cited
Scopus
Cited By
Altmetric
9.775
2.425
52
58
Tags
Anmerkungen
Besondere Publikation
Auf Hompepage verbergern

Zusatzinfos bearbeiten
Eigene Tags bearbeiten
Privat
Eigene Anmerkung bearbeiten
Privat
Auf Publikationslisten für
Homepage nicht anzeigen
Als besondere Publikation
markieren
Publikationstyp Artikel: Journalartikel
Dokumenttyp Wissenschaftlicher Artikel
Schlagwörter Acute Myeloid-leukemia; Chronic Lymphocytic-leukemia; Increased Flt3 Expression; European Leukemianet; Down-regulation; Cancer; Recommendations; Consolidation; Mitoxantrone; Abnormality
Sprache englisch
Veröffentlichungsjahr 2014
HGF-Berichtsjahr 2014
ISSN (print) / ISBN 0006-4971
e-ISSN 1528-0020
Zeitschrift Blood
Quellenangaben Band: 124, Heft: 8, Seiten: 1304-1311 Artikelnummer: , Supplement: ,
Verlag American Society of Hematology
Verlagsort Washington
Begutachtungsstatus Peer reviewed
Institut(e) CCG Pathogenesis of Acute Myeloid Leukemia (KKG-KPL)
POF Topic(s) 30504 - Mechanisms of Genetic and Environmental Influences on Health and Disease
Forschungsfeld(er) Immune Response and Infection
PSP-Element(e) G-521000-001
PubMed ID 24923295
DOI 10.1182/blood-2013-12-540716
WOS ID WOS:000342761900023
Scopus ID 84907303242
Erfassungsdatum 2014-06-15
[➜Korrektur melden]